Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Finance Watch: Regulus Shrinks To Preserve Cash, Ironwood Cuts Jobs Ahead Of Split

Executive Summary

Public Company Edition: Long-struggling Regulus is laying off employees and pausing its two clinical programs. Also, Ironwood is shuffling staff ahead of splitting into two companies and will cut 40 jobs in the process. And among several loan agreements and note sales, Tesaro borrows another $200m.


Related Content

Pipeline Watch: Phase III Trials Initiated For AMT-061, RP-G28 And APL-2
SOLO-1 Lynparza Data In First-Line Ovarian Cancer Seen Boosting AstraZeneca's PARP Edge
Ironwood Being Split In Two: Is Move To Thwart Activist Investor Sarissa?
Mesoblast’s Late-Stage Pipeline Could Be Game Changing: Are Investors Paying Attention?
IPOs In Review: Biopharma Offerings Bounced Back In 2017 As Returns Rose
Sienna CEO: IPO Investors Drawn By Experienced Dermatology Team
Regulus HCV Candidate Is Out, But New CEO Has BD Pedigree
Kura Oncology's Troy Wilson On Precision Medicine For Cancer
Regulus Rises On HCV Data, But Will Injection Find A Market?
IPO UPDATE: Intrexon rises 81% in 2 days; also Sophiris, Ruthigen, Acceleron, Iroko


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts